Celsion Corporation CLSN shares rose 3% to $2.42 after the company reported ongoing positive data from its Phase 2 DIGNITY study in breast cancer. Share volume was 41,000, compared to an all-day average of 56,000
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in